• Explore /
  • Poster
  • / Coformulated quavonlimab and pembrolizumab (pembro) in combination with lenvatinib (lenva) as first-line (1L) therapy for patients (pts) with advanced hepatocellular carcinoma (HCC): Phase 2 KEYSTEP-004 study.

Coformulated quavonlimab and pembrolizumab (pembro) in combination with lenvatinib (lenva) as first-line (1L) therapy for patients (pts) with advanced hepatocellular carcinoma (HCC): Phase 2 KEYSTEP-004 study.

Abstract Video & Slides Poster

Authors

null

Lorenza Rimassa

Department of Medical Sciences, Humanitas University, Pieve Emanuele & Humanitas Cancer Center, IRCCS Humanitas Research Hospital Rozzano, Milan, Italy

Lorenza Rimassa , Daneng Li , Masafumi Ikeda , Mark Yarchoan , Baek-Yeol Ryoo , Thibaud Kossler , Ho-Yeong Lim , Mariusz Kwiatkowski , Ting-Tsung Chang , Jee Hyun Kim , Andrea Casadei-Gardini , Masatoshi Kudo , Zhenggang Ren , Maria Varela Calvo , Josep M Llovet , Yayan Zhang , Ken Hatogai , Abby B. Siegel , Ann-Lii Cheng

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2024 ASCO Gastrointestinal Cancers Symposium

Session Type

Poster Session

Session Title

Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract

Track

Pancreatic Cancer,Hepatobiliary Cancer,Neuroendocrine/Carcinoid,Small Bowel Cancer

Sub Track

Therapeutics

Clinical Trial Registration Number

NCT04740307

Citation

J Clin Oncol 42, 2024 (suppl 3; abstr 484)

DOI

10.1200/JCO.2024.42.3_suppl.484

Abstract #

484

Poster Bd #

C9

Abstract Disclosures

Similar Posters

First Author: Richard S. Finn

First Author: Jaekyung Cheon

First Author: MinKe He

First Author: Elizabeth R. Plimack